Holen Sie sich die Stockscreener-App
24.30
6.07%
1.39
Schlusskurs vom Vortag:
$22.91
Offen:
$22.67
24-Stunden-Volumen:
1.04M
Relative Volume:
2.69
Marktkapitalisierung:
$737.02M
Einnahmen:
$339.92M
Nettoeinkommen (Verlust:
$-12.83M
KGV:
-56.58
EPS:
-0.4295
Netto-Cashflow:
$4.52M
1W Leistung:
+15.06%
1M Leistung:
+23.41%
6M Leistung:
-38.32%
1J Leistung:
+23.04%
1-Tages-Spanne:
$22.67
$24.34
1-Wochen-Bereich:
$20.64
$24.34
52-Wochen-Spanne:
$14.59
$44.28
Castle Biosciences Inc Stock (CSTL) Company Profile
Firmenname
Castle Biosciences Inc
Sektor
Branche
Telefon
866-788-9007
Adresse
1500 W. PARKWOOD AVE., FRIENDSWOOD, TX
Compare CSTL vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSTL
Castle Biosciences Inc
|
24.30 | 694.86M | 339.92M | -12.83M | 4.52M | -0.4295 |
TMO
Thermo Fisher Scientific Inc
|
513.03 | 187.95B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
196.19 | 136.75B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
551.50 | 43.78B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
136.01 | 38.27B | 7.23B | 1.41B | 1.09B | 4.979 |
NTRA
Natera Inc
|
261.91 | 37.34B | 2.50B | -226.32M | 71.51M | -1.6412 |
Castle Biosciences Inc Stock (CSTL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2021-04-30 | Eingeleitet | Lake Street | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-12-27 | Bestätigt | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | BTIG Research | Buy |
| 2019-08-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-08-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Castle Biosciences updates its melanoma test data, shares in biotech focus - Ad-hoc-news.de
Castle Biosciences (CSTL) Stock Sees Split Analyst Revisions As Price Targets Come Down - Yahoo Finance
Castle Biosciences (CSTL) Study Highlights Advancements in Melan - GuruFocus
Castle Biosciences, Inc. Actuals & Estimates (NASDAQ:CSTL) - TradingView
Castle Biosciences, Inc. Actuals & Estimates (TRADEGATE:086) - TradingView
Castle Biosciences’ melanoma test outperforms risk tool - Investing.com
Enterprise value to EBIT forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy - STLtoday.com
Precision Trading with Castle Biosciences Inc. (CSTL) Risk Zones - Stock Traders Daily
CSTL Forecast — Price Target — Prediction for 2027 - TradingView
Roth Capital Initiates Castle Biosciences at Buy - Moomoo
Price to earnings forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to EBITDA forward of Castle Biosciences, Inc. – NASDAQ:CSTL - TradingView
Enterprise value to revenue forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences (CSTL) Receives Buy Rating and $40 Target fro - GuruFocus
Enterprise value to EBIT forward of Castle Biosciences, Inc. – TRADEGATE:086 - TradingView
Castle Biosciences prioritizes people across patients, clinicians, and employees - Traders Union
Castle Biosciences Inc (CSTL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Castle Biosciences CFO receives Houston business award By Investing.com - Investing.com South Africa
Castle Biosciences CFO Frank Stokes Named Houston Business Journal CFO Awards Honoree - citybiz
Castle Biosciences CFO receives Houston business award - Investing.com
Castle Biosciences CFO Frank Stokes named among 22 Houston finance leaders - Stock Titan
Castle Biosciences Inc (CSTL) Institutional Confidence - TradingKey
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Castle Biosciences (CSTL) COO sells 8,587 shares, retains over 127K - Stock Titan
Castle Biosciences Inc (CSTL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Castle Biosciences Inc (CSTL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Castle Biosciences Inc (CSTL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Castle Biosciences Inc (CSTL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Castle Biosciences Inc (CSTL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Castle Biosciences Inc (CSTL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Castle Biosciences president & CEO Derek J. Maetzold sells $86,193 stock - Investing.com Nigeria
Castle Biosciences (CSTL) CEO Maetzold exercises options, trusts sell 4,172 shares - Stock Titan
CSTL (NASDAQ) Rule 144 notice: director sale notice for 4,152 shares - Stock Titan
Castle Biosciences (CSTL) Surpasses 100,000 TissueCypher Test Or - GuruFocus
Castle Biosciences TissueCypher clinical test orders surpass 100,000 milestone - Traders Union
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders By Investing.com - Investing.com Nigeria
Castle Biosciences' TissueCypher® Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus - StreetInsider
Castle Biosciences’ Barrett’s esophagus test reaches 100k orders - Investing.com
Technical Reactions to CSTL Trends in Macro Strategies - Stock Traders Daily
Castle Biosciences (CSTL) Slips Slightly as Shares Test Near-Term SupportPrice Action Signals - newsline.com
CSTL Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineGrowth Acceleration Report - newsline.com
How The Castle Biosciences (CSTL) Investment Story Is Evolving Without Fresh Analyst Commentary - Yahoo Finance
Earnings call transcript: Castle Biosciences Q1 2026 sees revenue growth - Investing.com
Castle Biosciences Q1 2026 slides: revenue beats, guidance raised - Investing.com
Castle Biosciences (CSTL) CEO sells shares and exercises options under 10b5-1 plan - Stock Titan
CSTL: Raised 2026 guidance after strong Q1 growth and expanded diagnostic test adoption - TradingView
CSTL: Raised 2026 revenue guidance on strong test growth and innovation in dermatology and GI - TradingView
Trading the Move, Not the Narrative: (CSTL) Edition - Stock Traders Daily
Maetzold-related trusts sell shares (CSTL) in multiple Form 144 trades - Stock Titan
Castle Biosciences (CSTL) director receives 11,766 RSUs in new equity grant - Stock Titan
Finanzdaten der Castle Biosciences Inc-Aktie (CSTL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):